



Targeted Molecular Therapy in Urological Cancer

Guest Editor:

Prof. Dr. Seetong Pang

Division of Urology, Department
of Surgery, Chang Gung Memorial
Hospital, Taoyuan 333, Taiwan

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editor

Dear Colleagues,

Molecular targeted therapies are attractive therapeutic approaches in cancer. Both multitargeted and highly selective kinase inhibitors are used to interfere with specific molecules to block cancer growth, progression, and metastasis. Many molecular targeted therapies have been approved by the Food and Drug Administration (FDA) and applied in the treatment of numerous cancer types, especially in urological cancers such as kidney cancer, prostate cancer, and urothelial cancer. Despite the recent understanding and identification of potential biomarkers for novel targeted therapies in urological cancer, there is still a lot of work to be done to make them effective. This Special Issue on "Targeted Molecular Therapy in Urological Cancer" aims to collect original research articles, clinical articles, or literature reviews that provide up-to-date insights to uro-oncologists on better ways to customize cancer treatments.

Prof. Dr. Seetong Pang
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)